ThermoGenesis Corp., had signed a distribution agreement with Celling Technologies for ThermoGenesis





ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, announced that it has signed a distribution agreement with Celling Technologies for ThermoGenesis’ MarrowXpress (MXP™) product line used for isolating stem cells from bone marrow.

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, announced that it has signed a distribution agreement with Celling Technologies for ThermoGenesis’ MarrowXpress (MXP™) product line used for isolating stem cells from bone marrow.

Celling Technologies is an innovator in the research, development and marketing of medical devices for use in regenerative medicine. Celling Technologies provides the scientific resources and technical expertise to provide services in the evolving field of stem cell therapy.

Celling Technologies will begin using the MXP to perform bone marrow stem cell separation for its existing point-of-care orthopedic procedures and perform clinical research utilizing this unique technology. The MXP offers a computerized control in the separation of stem cells from bone marrow aspirate which is first to market technology allowing surgeons to automate the steps with consistent cell separation accuracy and cryopreservation capabilities. In the field of regenerative medicine, a high concentration of stem cells delivered back to the patient offers an environment conducive to tissue regeneration.

Dr. William Osgood, Chief Executive Officer of ThermoGenesis said, “We are delighted to be partnering with Celling Technologies. Their business model, which incorporates a high level of on-site service to clinicians, was a very important factor in our decision to establish our relationship,” he added.

Dr. Richard Suzuki, Director of Research & Development of Biomaterial Engineering for Celling Technologies noted, We are excited about the significant market potential available to the ThermoGenesis product offering and the data we can collect through the research and development of stem cells utilizing their technology. The idea of automated controlled accuracy to provide consistent results to the patient and the market potential for cryopreservation of adult stem cells puts the technology of ThermoGenesis in a great position for leadership in an emerging industry

Bone marrow derived stem cells are the dominant source of stem cells studied in regenerative medicine clinical trials for treating several large patient population diseases and injuries, including a number of orthopedic surgeries in the U.S. and international markets.